Weight Loss Injections Explained: The Approved Medicines, How They Differ and Who Qualifies

At a Thanksgiving table last fall, three cousins discovered they were on the same once-a-week pen. One had lost 40 pounds and felt steady for the first time in decades. One had quit after six queasy weeks. The third was quietly wondering whether the vials she had ordered from a website were even the same medicine. Their conversation is happening in living rooms everywhere, and it explains why weight loss injections are one of the most searched health topics as of January 2026.

The surge has real causes. A head-to-head trial published in 2025 finally compared the two leading medicines directly. Regulators added new approved uses, including heart protection, sleep apnea and a liver disease, and a pill form of semaglutide reached the market. At the same time, viral claims about melting fat and quitting once you hit goal spread faster than the trial data.

This explainer sorts what the evidence shows from what the algorithm shows, medicine by medicine.

What are weight loss injections and how do they work?

Every time you eat, the lining of your small intestine releases a hormone called GLP-1, short for glucagon-like peptide-1. It tells the pancreas to release insulin, slows the rate at which the stomach empties, and signals to appetite centers in the brain that a meal has landed. The natural version disappears within minutes. The medicines in today’s weight loss injections are engineered copies that linger for days.

Pharmacologists call these medicines agonists, a term that simply means a drug that switches on the same receptor a hormone would. Semaglutide (sold as Wegovy for weight, Ozempic for type 2 diabetes) and liraglutide (Saxenda for weight, Victoza for diabetes) act on the GLP-1 receptor alone. Tirzepatide (Zepbound for weight, Mounjaro for diabetes) also switches on a second receptor for a hormone called GIP, glucose-dependent insulinotropic polypeptide, another gut signal involved in how the body handles a meal.

The practical result shows up in three places. Meals feel filling sooner and stay filling longer because the stomach empties more slowly. Blood sugar swings flatten, which reduces the mid-afternoon urge to graze. Most striking to many patients, the constant background chatter about food, sometimes nicknamed food noise, turns down. People describe leaving half a plate without willpower entering the picture.

None of this burns fat directly. Weight comes off because people eat several hundred fewer calories a day, week after week, and the body draws on stored energy to cover the gap. That distinction matters for expectations: the medicine changes appetite, and appetite changes intake, and intake changes weight. Remove the medicine and the original appetite signals return, which is why the trials treat these as long-term therapies for a chronic condition rather than a short course.

All three approved medicines are given as a shallow injection under the skin of the abdomen, thigh or upper arm, using a prefilled pen. The newer two are taken weekly; liraglutide is a daily injection.

What changed recently: the approvals and trials worth knowing

The pace of news since 2021 explains much of the current attention. These are the dated milestones that shaped the category, drawn from the prescribing information summarized on MedlinePlus and NIH pages.

• June 2021: The FDA approved semaglutide (Wegovy) for chronic weight management in adults, the first weekly injection in this class approved for weight rather than diabetes.
• December 2022: Wegovy’s approval expanded to adolescents aged 12 and older with obesity, joining liraglutide (Saxenda), which had gained a similar pediatric indication in 2020.
• November 2023: Tirzepatide (Zepbound) was approved for weight management in adults, the first medicine acting on both GLP-1 and GIP receptors.
• March 2024: Wegovy received an additional indication to reduce the risk of heart attack, stroke and cardiovascular death in adults with established heart disease and overweight or obesity, based on the SELECT trial.
• December 2024: Zepbound was approved to treat moderate to severe obstructive sleep apnea in adults with obesity, the first medicine ever approved for that condition.
• Late 2024 to early 2025: The FDA declared the national shortages of tirzepatide and then semaglutide resolved, which changed the legal footing for pharmacies that had been compounding copies during the shortage.
• May 2025: The SURMOUNT-5 trial, the first direct comparison of tirzepatide against semaglutide for weight, was published in the New England Journal of Medicine.
• August 2025: Wegovy was approved for adults with a liver condition called MASH, metabolic dysfunction-associated steatohepatitis, in which fat buildup inflames and scars the liver.
• Late 2025: A pill form of semaglutide for weight management was cleared in the United States, giving patients an alternative to injections.

Taken together, these changes moved the conversation from can these medicines help people lose weight to which health outcomes improve when they do. That is a meaningful shift, and it is the reason clinicians increasingly frame them as treatments for a chronic disease with complications, not cosmetic tools.

Which weight loss injections are FDA approved?

Three injectable medicines carry an FDA approval specifically for chronic weight management. Two other pens contain the same active ingredients but are approved only for type 2 diabetes. The distinction trips up almost everyone, so here it is in one place.

Brand	Active ingredient	Hormone pathways	Approved for	Approved ages
Wegovy	Semaglutide	GLP-1	Chronic weight management; cardiovascular risk reduction in established heart disease; MASH	12 and older (weight)
Zepbound	Tirzepatide	GLP-1 and GIP	Chronic weight management; moderate to severe obstructive sleep apnea with obesity	Adults
Saxenda	Liraglutide	GLP-1	Chronic weight management	12 and older
Ozempic	Semaglutide	GLP-1	Type 2 diabetes; cardiovascular and kidney risk reduction in diabetes	Adults
Mounjaro	Tirzepatide	GLP-1 and GIP	Type 2 diabetes	Adults

Two patterns in the table deserve a second look. First, the approved uses have widened beyond the number on the scale. Heart, liver and airway indications now sit on the labels, which reflects trials measuring events such as heart attacks and apnea episodes rather than pounds alone. Second, the weight-management brands and the diabetes brands share an ingredient but differ in labeling, studied populations and the way the dose is built up over time. Prescribing a diabetes brand for weight in someone without diabetes is off-label, meaning outside the approved indication. It happens, and clinicians may have reasons, but the evidence base and label protections belong to the weight-management products.

Liraglutide, approved in 2014, is the oldest of the three and the only daily injection. Its weight results are more modest, and generic versions began appearing in 2024, which matters for access in some health systems. Every choice among them rests with the prescribing clinician after reviewing a person’s history.

Wegovy vs Ozempic: same molecule, different label

Ask a search engine how long it takes to lose 20 pounds on Ozempic and you will get thousands of answers, most of them missing a basic point. Ozempic is approved to treat type 2 diabetes. Wegovy is approved for weight. They contain the same molecule, semaglutide, made by the same manufacturer, in similar-looking pens.

The differences lie in three areas. The weight-management product is studied and labeled at a higher maintenance level than the diabetes product, and it follows its own step-up schedule designed to reach that level. The trial populations were different: the STEP program that supports Wegovy enrolled people with obesity, most of whom did not have diabetes, while the SUSTAIN program behind Ozempic enrolled people with type 2 diabetes and tracked blood sugar as the main outcome. And the labels list different approved uses, which affects how the medicines are reviewed by health plans and monitored by clinicians.

Weight loss still occurs on Ozempic. In diabetes trials, people typically lost a modest amount, noticeably less than the roughly 15 percent average seen in Wegovy’s flagship trial. Part of the gap is the dose; part is biology, since people with type 2 diabetes tend to lose somewhat less weight on these medicines than people without it, a finding that has held across several studies.

Why does the confusion persist? Early in the Wegovy shortage of 2022 and 2023, some clinicians prescribed Ozempic off-label for weight, and social media adopted Ozempic as shorthand for the whole class. The habit stuck even as the supply recovered.

If you have type 2 diabetes and excess weight, either product might be discussed, and the choice depends on which outcomes your clinician is prioritizing. If you do not have diabetes, the weight-management label is the one that applies to you. Either way, the decision is the prescriber’s to make, ideally with you understanding exactly which label your pen carries.

Zepbound and Mounjaro: how tirzepatide differs from the others

Tirzepatide is the newcomer, and it arrived with the largest average weight loss ever recorded for a medicine in a randomized trial. Its distinguishing feature is that it activates two receptors instead of one. GLP-1 handles fullness and slower stomach emptying; GIP appears to influence how fat tissue stores and releases energy and may blunt some of the nausea that comes from GLP-1 stimulation alone. Researchers still debate exactly how much each pathway contributes, but the combined result is consistent across trials.

In SURMOUNT-1, adults with obesity and no diabetes lost, on average, between about 15 and 21 percent of their body weight over 72 weeks depending on the dose level reached, compared with roughly 3 percent on placebo. For someone starting at 250 pounds, the upper end of that range is about 50 pounds. More than nine in ten participants lost at least 5 percent, the threshold most clinicians consider meaningful for health.

The direct comparison arrived in 2025. SURMOUNT-5 randomized adults with obesity to tirzepatide or semaglutide at their approved weight-management levels for 72 weeks. Tirzepatide produced an average loss of about 20 percent versus about 14 percent for semaglutide. Both groups did well; the gap was clear and statistically robust.

Zepbound’s second indication, obstructive sleep apnea, came from the SURMOUNT-OSA trials, where participants with obesity saw large reductions in the number of breathing interruptions per hour of sleep, with many no longer meeting criteria for moderate or severe disease.

What tirzepatide lacks, for now, is a completed cardiovascular outcomes trial in people without diabetes comparable to semaglutide’s SELECT. A large trial is underway. Until it reports, the heart-protection claim belongs to semaglutide on the evidence, and larger weight loss belongs to tirzepatide. Those are different strengths, and which one matters more depends on the person sitting in the exam room.

What the evidence actually says, and how strong it is

Not every claim about weight loss injections rests on the same foundation. Grading the evidence separates what is established from what is plausible and what is still guesswork.

Strong evidence (large randomized controlled trials): A randomized controlled trial assigns people by chance to a medicine or a placebo, which is the most reliable way to prove cause and effect. The STEP, SURMOUNT and SCALE programs each enrolled thousands of participants and ran for well over a year. Their findings are settled: semaglutide produces an average loss near 15 percent, tirzepatide around 15 to 21 percent, liraglutide around 8 percent, each compared with 2 to 3 percent on placebo alongside the same lifestyle counseling. Cardiovascular protection with semaglutide is also strong: SELECT followed more than 17,000 adults with heart disease for over three years and found a 20 percent relative reduction in heart attack, stroke and cardiovascular death.

Moderate evidence (observational data): Observational studies watch what happens in real patients without random assignment, so they show associations rather than proof. Real-world data suggest weight loss outside trials tends to be somewhat smaller, partly because many people stop within a year. Observational signals also flagged a possible link between semaglutide and a rare optic nerve condition, and earlier concerns about suicidal thoughts, which regulators reviewed and did not find causal as of 2024. Signals like these warrant monitoring, not alarm.

Expert opinion and open questions: No trial has yet followed patients beyond about four years. How much lean muscle is lost, whether bone density suffers, the safest approach to pausing or tapering, and effects in people with a BMI under 27 remain matters of clinical judgment. Claims that these medicines reduce addictive behaviors or dementia risk come from early or observational data and should be described as hypotheses.

The honest summary: the weight-loss effect and semaglutide’s heart benefit are among the best-proven results in modern metabolic medicine. Nearly everything about the very long term is still being written.

Who qualifies for weight loss shots?

Eligibility on the approved labels is written in terms of body mass index, or BMI, a ratio of weight to height that estimates body fat across a population. For adults, all three weight-management products are approved for people with a BMI of 30 or higher, or a BMI of 27 or higher together with at least one weight-related condition. Those conditions typically include high blood pressure, type 2 diabetes, abnormal cholesterol, obstructive sleep apnea or established cardiovascular disease. Wegovy and Saxenda extend to adolescents aged 12 and older whose BMI sits at or above the 95th percentile for their age and sex; Zepbound remains adults only.

Meeting a number does not automatically mean the medicine is appropriate. Prescribers screen for situations where these medicines are avoided. A personal or family history of medullary thyroid cancer or a genetic syndrome called MEN2 rules them out entirely, based on tumors seen in rodent studies. Pregnancy, breastfeeding or plans to conceive soon are reasons to defer, since fetal effects are unknown and the guidance is to stop well before trying to conceive. A history of pancreatitis, severe gastrointestinal disease such as gastroparesis (delayed stomach emptying), or an eating disorder calls for careful individual judgment. Type 1 diabetes is not an approved use.

BMI itself has limits. It overstates fat in very muscular people and can understate health risk in others; the WHO notes that people of some Asian backgrounds face metabolic risk at lower BMI values. Many clinicians now weigh waist circumference, blood tests and existing conditions alongside the number.

People asking whether weight loss shots are an option for losing the last ten pounds before a wedding are asking about use outside the label. There is little trial evidence in that group and no safety data to support it, and cosmetic use is not an approved indication. The person who decides whether anyone qualifies is the treating clinician, after a full history and examination.

How much weight do people lose, and how fast?

The trial averages give a ceiling and a timeline. Semaglutide’s headline result, about 15 percent over 68 weeks, means a person starting at 220 pounds lost roughly 33 pounds in about 16 months. Tirzepatide’s upper range, about 21 percent over 72 weeks, translates to about 46 pounds for the same person. Liraglutide’s 8 percent means closer to 18 pounds over a year.

Averages hide the spread. In every trial, some participants lost more than a quarter of their weight while a minority lost less than 5 percent. Roughly one in seven people on semaglutide and about one in ten on tirzepatide fell into that low-response group. Clinicians cannot yet predict who will respond, which is why labels build in a check at a few months to see whether the medicine is doing enough to continue.

The curve is not a straight line. Because each medicine starts low and increases in steps over several months to limit nausea, early losses are gentler than the eventual pace. The steepest decline typically arrives between months three and nine. Around the one-year mark the curve flattens into a plateau, which is the body settling at a new balance rather than the medicine failing.

That timeline answers two of the most common questions. Losing 20 pounds on semaglutide usually takes several months to a year depending on starting weight and response, and it is a realistic goal only if the medicine is prescribed for you in the first place. Losing 5 pounds in a month is well within a healthy range with or without medication; the CDC describes 1 to 2 pounds per week as a sustainable pace, and both leading injections tend to produce something close to that during the active phase.

Speed is not the metric that matters most. Weight lost slowly while eating enough protein and moving regularly preserves more muscle than the same pounds lost quickly, and muscle is what keeps the loss from becoming frailty.

What are the side effects of weight loss injections?

The most common side effects are the predictable consequences of a stomach that empties slowly. In the main semaglutide trial, about 44 percent of participants reported nausea at some point, roughly 30 percent diarrhea, and about a quarter each vomiting or constipation. Tirzepatide’s numbers were similar. Most of these symptoms cluster in the weeks after each step up in dose and fade as the body adjusts; between 4 and 7 percent of trial participants stopped because of them.

Less common effects deserve more attention than their frequency suggests. Gallbladder problems, including gallstones, occurred in about 2 to 3 percent of people, a rate linked to rapid weight loss in general as well as the medicine. Pancreatitis, inflammation of the pancreas, is rare but serious and shows up as severe abdominal pain that often travels to the back. Kidney injury has been reported, nearly always in people who became dehydrated from persistent vomiting or diarrhea. In people who also take insulin or a sulfonylurea for diabetes, low blood sugar becomes more likely.

Every product in the class carries a boxed warning about thyroid C-cell tumors seen in rodents. Whether this translates to humans is unknown; the precaution is to avoid the medicines in anyone with a personal or family history of medullary thyroid cancer or MEN2.

Newer concerns have emerged from practice rather than trials. Anesthesiologists now ask about these medicines before surgery because a slower-emptying stomach raises the risk of inhaling stomach contents during sedation. Semaglutide has been associated with worsening of existing diabetic eye disease in some trials, and observational data have raised a possible link to a rare optic nerve stroke. Hair thinning, a familiar companion of rapid weight loss from any cause, appears in a small fraction of users.

The gaunt look nicknamed Ozempic face is not a drug effect at all. It is facial fat loss, which happens with any substantial weight loss, at any age, by any method.

What happens when you stop weight loss injections?

This is the question that separates realistic expectations from disappointment, and the evidence is unusually clear. In an extension of the STEP 1 trial, participants who stopped semaglutide and the accompanying lifestyle support regained, on average, about two-thirds of the weight they had lost within a year. The cardiometabolic improvements, including blood pressure and cholesterol, drifted back toward baseline over the same period.

Tirzepatide tells the same story from a different angle. In SURMOUNT-4, everyone took the medicine for 36 weeks and lost around 20 percent of their weight. Then half were switched, without knowing, to placebo. Over the following year, those on placebo regained about 14 percentage points; those who continued lost a further 5 percent. The medicine was doing something the whole time.

Biology explains the rebound. Excess weight is not simply a habit; the body defends its weight through hormones such as leptin and ghrelin that increase hunger and lower energy expenditure after weight loss, a response that can persist for years. The injections counter those signals directly. Remove them and the signals resume, and appetite follows.

This is why major guidelines and both major manufacturers describe these medicines as long-term treatments for a chronic condition, comparable to blood pressure medicine rather than a course of antibiotics. Some people do stop successfully, especially those who used the active phase to build durable eating and strength-training habits, but they are the exception in the published data.

Two practical points follow. Nobody should stop or stretch out their injections on their own, whether to save supply, avoid side effects or test whether they still need the medicine; each of those situations is a conversation with the prescriber, who may have alternatives. And anyone starting should ask at the outset what the plan looks like in year two and beyond, including what happens if supply, tolerance or circumstances change.

Are compounded or online weight loss shots the same medicine?

The third cousin at that Thanksgiving table asked the right question. Products marketed online as semaglutide or tirzepatide often come from compounding pharmacies or from sellers with no pharmacy license at all, and neither category is the same as an FDA-approved product.

Compounding is the practice of a pharmacist preparing a customized medicine for an individual patient, for example when someone is allergic to an ingredient in the commercial version. It is legal in defined circumstances and serves a genuine need. Compounded drugs, however, are not reviewed by the FDA for safety, effectiveness or quality before they reach a patient. During the shortages of 2022 through early 2025, federal rules allowed broader compounding of these molecules to fill the gap. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which ended that allowance for mass-produced copies, though disputes and transition periods followed.

The agency has documented specific problems with some compounded versions: dosing errors from unfamiliar concentrations and syringes, use of salt forms of semaglutide that differ from the approved active ingredient, and products that contained the wrong amount or unidentified ingredients. Emergency departments have reported overdoses traced to measurement mistakes with multi-use vials.

A separate category deserves plain language. Research peptides and investigational molecules such as retatrutide are marketed on some websites as next-generation weight loss shots. These are experimental compounds studied only in controlled trials. They are not approved for any use, they are not legally for sale as medicines, and they are not for self-use.

The safest position is the simplest one: the only products with trial data behind them are the approved ones, obtained through a prescription from a licensed clinician and dispensed by a licensed pharmacy. Anything that arrives without those two steps carries risks that no published study has measured.

Common myths about weight loss injections

Viral claims travel faster than trial results. These are the ones clinicians hear most, corrected against the evidence.

Myth: the injection melts fat. Nothing in these medicines acts on fat tissue to dissolve it. They reduce appetite, people eat less, and the body draws down stored energy. The mechanism is the same one behind any calorie deficit; the medicine makes the deficit sustainable.

Myth: it is cheating, or the easy way out. Excess weight is driven by hormonal signals that most people cannot override through effort alone, which is why the average lifestyle program yields 5 to 10 percent loss and much of it returns. Treating a hormonal problem with a hormonal medicine is not a moral shortcut; it is medicine.

Myth: once you reach goal, you stop. Trial data show most weight returns within a year of stopping. The approved uses are for chronic weight management, and any change to treatment is a decision for the prescriber.

Myth: everyone loses 20 percent. That figure is an average from tirzepatide’s best-performing group. Roughly one in ten to one in seven people respond minimally, and real-world results are typically smaller than trial results.

Myth: Ozempic face is a drug side effect. It is facial fat loss from losing weight, seen after bariatric surgery and dieting alike.

Myth: these are only for people with diabetes. Wegovy, Zepbound and Saxenda are approved for weight management regardless of diabetes status, within the BMI criteria.

Myth: they are safe for anyone who wants to slim down. The trials enrolled people with obesity or overweight plus complications. There is no safety evidence for people below those thresholds, and the boxed warning and contraindications apply to everyone.

Myth: a product that lists semaglutide is semaglutide. Compounded and unlicensed products may contain different salt forms, different amounts or unknown ingredients, and none has passed FDA review.

What is the best injectable for losing weight?

There is no single best weight loss injection, and anyone who says otherwise is selling something or reading a single trial. There is, however, a clear picture of what each medicine does best.

If the question is which produces the largest average loss, the answer is tirzepatide. The SURMOUNT-5 head-to-head trial showed about 20 percent versus about 14 percent for semaglutide over 72 weeks, with more people on tirzepatide reaching the larger milestones of 15 and 25 percent loss. That is the strongest randomized evidence available on comparative efficacy.

If the question is which has proven it protects the heart in people with obesity and established heart disease, the answer is semaglutide. SELECT’s 20 percent reduction in major cardiovascular events over more than three years is the kind of outcome data tirzepatide has not yet completed in that population. Semaglutide also carries the liver indication and the longest track record among weekly products.

If the question is which has the most years of use, it is liraglutide, on the market since 2010 for diabetes and 2014 for weight, with results that are smaller but well characterized, and now available generically in some markets.

For an individual, the most useful definition of best is different: the medicine you can tolerate and continue. Discontinuation, not efficacy, is the biggest predictor of long-term results. Some people find tirzepatide gentler on the stomach; others do better on semaglutide; a few need the daily rhythm of liraglutide for reasons of their own. Existing conditions steer the choice too. A person with heart disease might reasonably start with the medicine that has heart outcome data, while a person with sleep apnea might be steered toward the one approved for it.

Every one of those trade-offs sits with the prescribing clinician, who can weigh your history, your other medicines and your goals against the evidence. The best injectable is the one chosen that way.

When to see a doctor

Anyone considering a weight loss injection should begin with a clinician, not a website, because eligibility screening, baseline blood tests and a review of existing medicines are part of safe prescribing. Once treatment is underway, some symptoms should not wait for the next scheduled visit.

Seek urgent care or emergency help for:

• Severe, persistent abdominal pain, especially pain that spreads to the back, with or without vomiting, which can signal pancreatitis.
• Pain under the right ribs, fever, yellowing of the skin or eyes, or clay-colored stools, which can indicate a gallbladder problem.
• Vomiting or diarrhea that prevents you from keeping fluids down for more than a day, or signs of dehydration such as dizziness, very little urine or a racing heart.
• Shakiness, sweating, confusion or fainting suggestive of low blood sugar, particularly if you also take insulin or a sulfonylurea.
• Sudden change in vision, including blurring or loss of vision in one eye.
• Swelling of the face or throat, hives or difficulty breathing, which may indicate an allergic reaction.
• New or worsening thoughts of self-harm or marked changes in mood.

Contact your prescriber promptly for:

• A lump or swelling in the neck, hoarseness or difficulty swallowing, which the label lists as reasons to evaluate the thyroid.
• Food feeling stuck, severe reflux or bloating that does not settle.
• Planned surgery, a procedure requiring sedation, or a colonoscopy, since anesthesiologists need to know about these medicines in advance.
• Plans to become pregnant, a positive pregnancy test or breastfeeding.
• Side effects that persist beyond the adjustment period, or weight that has not changed meaningfully after a few months.

Never stop, pause, split or stretch doses on your own, and never combine an approved product with any compounded or online version. Every adjustment, including whether to continue at all, belongs to the clinician who prescribed the medicine and knows your full history.

Frequently asked questions

What is the best injectable for losing weight?

No single injectable is best for everyone. Tirzepatide (Zepbound) produced the largest average loss in a direct trial, about 20 percent versus 14 percent for semaglutide (Wegovy) over 72 weeks. Semaglutide has the strongest proof of heart protection in people with obesity and heart disease. Liraglutide (Saxenda) has the longest record but smaller results. Your clinician weighs tolerance, health conditions and goals to choose.

How can I lose 100 pounds in a healthy way?

Losing 100 pounds safely usually takes one to two years under medical supervision, at a pace of about 1 to 2 pounds a week. For most people that combines a structured eating plan with adequate protein, regular strength training to protect muscle, sleep and stress support, and often a prescribed weight-management medicine or bariatric surgery. A clinician can screen for underlying conditions and monitor labs, blood pressure and nutrition along the way.

How long will it take to lose 20 lbs on Ozempic?

Ozempic is approved for type 2 diabetes, not weight, so its trials measured blood sugar first. On semaglutide at weight-management levels, participants lost about 15 percent of body weight over 68 weeks, meaning 20 pounds typically took several months to a year depending on starting weight. Early months are slower because the dose is built up gradually. Individual response varies widely, and only a prescriber can decide whether semaglutide fits your situation.

Is it possible to lose 5 pounds in a month?

Yes, 5 pounds in a month is a realistic and healthy goal for most adults with excess weight. The CDC describes 1 to 2 pounds per week as a sustainable pace, which works out to 4 to 8 pounds monthly. That rate is achievable through a modest calorie deficit, more daily movement and better sleep, with or without medication. Faster loss tends to sacrifice more muscle and is harder to maintain.

What is the difference between Wegovy and Ozempic?

Both contain semaglutide, but Wegovy is approved for chronic weight management, cardiovascular risk reduction and MASH, while Ozempic is approved for type 2 diabetes. Wegovy is studied and labeled at a higher maintenance level with its own step-up schedule, and its trials enrolled people with obesity rather than diabetes. Using Ozempic for weight in someone without diabetes is off-label, a decision that rests with the prescribing clinician.

Can I get weight loss shots if I am not obese?

The approved labels cover adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes or sleep apnea. Below those thresholds, there is little trial evidence and no safety data, and cosmetic use is not an approved indication. A clinician may consider waist size and health risks alongside BMI, but eligibility is their determination.

Do weight loss injections cause muscle loss?

Some lean mass is lost with any significant weight loss, and body-composition substudies of these trials found that roughly a quarter to 40 percent of the weight lost was lean tissue, a proportion similar to diet-induced loss. Adequate protein and regular resistance training reduce that share. Whether the medicines themselves accelerate muscle loss beyond what the weight change explains is still an open research question.

Do you have to stay on weight loss shots forever?

The evidence points that way for most people. In trial extensions, participants who stopped semaglutide regained about two-thirds of their lost weight within a year, and those switched from tirzepatide to placebo regained roughly 14 percentage points. Labels describe chronic weight management as a long-term treatment. Some people maintain after stopping, especially with strong habits, but any decision to pause or stop belongs to your prescriber.

Are compounded semaglutide or tirzepatide safe?

Compounded versions are not FDA-approved and have not been reviewed for safety, quality or effectiveness. The FDA has documented dosing errors, unapproved salt forms and products with incorrect or unidentified ingredients. With the national shortages declared resolved in late 2024 and early 2025, the allowance for mass-compounded copies ended. Experimental peptides sold online are not approved for any use and are not for self-use.

Is the semaglutide pill as effective as the injection?

A pill form of semaglutide for weight management was cleared in the United States in late 2025. In its trial, average weight loss was in a range broadly comparable to the injection, though results are not identical and the pill has its own instructions around timing with food. It offers an option for people who cannot or prefer not to inject. Which form suits you is a decision for your clinician.

References

• Semaglutide Injection – MedlinePlus Drug Information
• Tirzepatide Injection – MedlinePlus Drug Information
• Prescription Medications to Treat Overweight and Obesity – NIH NIDDK
• GLP-1 Agonists – Cleveland Clinic

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.